The Mount Sinai Hospital has performed the first procedure in NYC using the HYDROS Robotic System, a cutting-edge technology designed to treat benign prostatic hyperplasia (BPH). The minimally invasive procedure preserves continence and sexual function, offering new hope for patients experiencing symptoms of BPH.
Dr. Jared M. Kutzin has been elected President of the Society for Simulation in Healthcare (SSH), a position he will hold for one year. He aims to expand affiliations and strategic partnerships worldwide and develop relationships with emergency medical services partners.
Researchers found that wearable devices can identify, differentiate, and predict flares in IBD by analyzing circadian patterns of heart rate variability, heart rate, oxygenation, and daily activity. The study showed that these metrics changed up to seven weeks before flares developed, enabling continuous disease monitoring.
A Mount Sinai-led team has developed an automated machine learning method that analyzes video recordings of clinical sleep tests to detect REM sleep behavior disorder (RBD) with nearly 92% accuracy. RBD is a sleep condition that causes abnormal movements during REM sleep and is often an early sign of Parkinson's disease or dementia.
Researchers have identified a novel mechanism controlling circadian gene expression and behavioral rhythms through chemical bonding of monoamine neurotransmitters to histone proteins. This discovery could lead to targeted therapies for conditions involving circadian rhythm disruptions, such as insomnia and depression.
Mount Sinai researchers have made significant progress in understanding how human beta cell regenerative drugs work, potentially leading to a cure for diabetes. The study suggests that these drugs may be able to induce lineage conversion in human pancreatic islets, providing a new source of beta cells.
Valentin Fuster, MD, PhD, has made significant contributions to the understanding of atherosclerosis through his research on inflammation, thrombosis, and treatment breakthroughs. His work has led to major advances in diagnosis and therapy, including the development of a cardiovascular 'polypill' that reduces cardiovascular mortality.
The Mount Sinai Health System has received the 2024 CHIME Digital Health Most Wired recognition as a certified level 9 in acute care and level 8 in ambulatory care. The system leverages digital health solutions to enhance patient care and reduce administrative burden.
The Hamilton and Amabel James Center for Artificial Intelligence and Human Health solidifies Mount Sinai's leadership in delivering patient care through innovative AI tools and technologies. The interdisciplinary center combines AI, data science, and genomics to revolutionize diagnosis and treatment.
Researchers developed a novel approach to deliver therapeutics into the brain, overcoming the blood-brain barrier. The BCC platform successfully reduced harmful gene activity in models of ALS and Alzheimer's disease, offering new possibilities for treating neurological and psychiatric diseases.
GNOMX Corp. has been awarded a contract by the US Department of Health and Human Services to develop an immune dysregulation host-based assay to predict sepsis patient readmission risk. The assay aims to reduce hospital expenses and improve patient outcomes.
Researchers at Mount Sinai identified a task-grouping approach that can help hospitals reduce AI-related costs by up to 17-fold while maintaining model performance. By grouping clinical tasks, LLMs can handle them simultaneously without significant drops in accuracy.
Researchers at Mount Sinai trained an AI algorithm on over 16 million seconds of video footage from newborns in the NICU to predict sedation and cerebral dysfunction. The study shows promise for a minimally invasive, scalable method for continuous neurologic monitoring.
Mount Sinai researchers discovered a neural mechanism for memory integration that involves replaying experiences, integrating new information with existing memories, and linking memories across time. This finding has implications for understanding adaptive and maladaptive memory processes, such as PTSD.
Researchers found that expanded screening protocols identified eight cases of Candida auris that would have gone undiagnosed, enabling prompt isolation and disinfection precautions. The new approach promotes early detection and targeted precautions to reduce hospital outbreaks.
Researchers discovered that ovarian cancer produces IL-4 to create a protective environment, resisting immunotherapy. Blocking IL-4 with dupilumab-like drugs could enhance immunotherapy for ovarian cancer.
A new study found that the heart sends signals to the brain to increase sleep after a heart attack, promoting healing and reducing inflammation. This communication between the heart and brain is mediated through the immune system and can lead to improved recovery and reduced risk of further cardiovascular events.
A study found that using an orbital atherectomy device to remove calcium from blocked coronary arteries before stenting procedures did not improve patient outcomes. The device was used on patients with moderately severe calcification, rather than extreme cases, and did not show significant benefits.
Researchers at Mount Sinai have developed an Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform, a new antibody approach that can target multiple stable regions of viruses like SARS-CoV-2. The platform uses engineered nanobodies to bind to the virus, providing a more durable defense against evolving viruses.
KiNet is an interactive web portal that enables researchers to visualize and study kinase-substrate interactions in systemwide contexts. This facilitates the understanding of kinase functions and their implications in diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases.
Brendan G. Carr, MD, MS, receives the Colin C. Rorrie Award for Excellence in Health Policy, recognized for his work on building regional systems for emergency care and advocating for increased collaboration between public and private sectors. Ugo Ezenkwele, MD, MPH, receives the Leon L. Haley Jr. Award for Excellence in Diversity, Inc...
A new study published in the Journal of the American College of Cardiology found that subclinical atherosclerosis is independently associated with the risk of dying from any cause. The study also showed that monitoring the progression of atherosclerosis can improve the prediction and prevention of death from any cause.
A Mount Sinai study links prediabetes among young people with a higher likelihood of gestational diabetes and hypertensive disorders during pregnancy. The findings highlight the need for clear clinical guidance on screening and counseling youth with elevated blood glucose levels.
Researchers at the Icahn School of Medicine at Mount Sinai have identified a novel genetic variant associated with intellectual capacities and educational outcomes. Tandem repeats in the AFF3 gene were found to disrupt genetic instructions, impacting cognitive abilities.
The Mount Sinai Health System has expanded its psychedelic psychotherapy research center with a new facility in upper Manhattan. The Center will support rigorous clinical trials for well-known compounds like MDMA, psilocybin, and ketamine, which have shown potential in alleviating symptoms of PTSD, depression, anxiety, and other stress...
The new center aims to provide state-of-the-art genomic services to patients with difficult-to-diagnose diseases, aiming to shed light on undiagnosed conditions and uncover rare variations of more common diseases. The grant will enable the provision of advanced diagnostic services to alleviate the burden of these disorders.
The Mount Sinai Health System is deploying blood-based biomarkers and confirmatory tests for Alzheimer's disease and related dementias, enabling early detection and intervention. The system aims to stratify patients rapidly, non-invasively, and cost-effectively.
Researchers identified changes in the UBR4 gene as a key driver of fibromuscular dysplasia, a blood vessel disorder affecting up to five percent of adults. The discovery could lead to therapeutic approaches for the condition, particularly beneficial for women who account for 90% of cases.
Researchers at Mount Sinai developed an AI model that predicts brain blood pressure using noninvasive data, enabling swift detection of critical changes and potentially saving lives. The study showed strong performance in detecting intracranial pressure within seconds.
Researchers found that an aging immune system spurs tumor growth by promoting inflammation, which can drive cancer development. Blocking specific inflammatory pathways may reverse this process, offering a potential new approach to preventing cancer development in humans.
A new five-year grant will explore the mammary gland's influence on metabolic diseases like obesity and type 2 diabetes. The research aims to identify specific hormones produced by the mammary gland, known as mammokines, which may impact obesity and diabetes in mothers and offspring.
Researchers at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles that could revolutionize how cancer and other diseases are diagnosed. These molecules undergo changes when cancer is present, suggesting their potential as biomarkers for detecting prostate cancer.
A new study found that the incidence of hepatitis C virus (HCV) reinfection among men with HIV is 10-fold higher than primary infection rates in New York City. The researchers identified receiving semen in the rectum as the only risk factor for reinfection, contradicting previous assumptions about transmission routes.
Researchers from Mount Sinai and City of Hope demonstrate a combination treatment that increases human insulin-producing beta cells by 700% in mice with diabetes. This breakthrough could lead to new treatments for the hundreds of millions of people with diabetes worldwide.
A recent study published in Nature Medicine has shown that pulsed field ablation (PFA) is a safe and effective treatment for patients with atrial fibrillation. The study analyzed over 17,600 patients and found no significant risk of esophageal damage or other complications, increasing confidence in the use of PFA technology.
The Mount Sinai researchers have developed a comprehensive epidemiological dataset for youth diabetes and prediabetes research, derived from NHANES data collected from 1999 to 2018. The newly launched POND portal aims to facilitate an understanding of factors that may influence youth diabetes risk.
Researchers found major differences between postmortem and living prefrontal cortex brain tissues, with higher levels of RNA editing in postmortem tissues. These discoveries will shape the development of diagnostics and therapies for brain diseases, highlighting the need to study both living and postmortem samples.
A recent study published in Critical Care Medicine found that real-time machine learning alerts significantly improved patient outcomes by predicting clinical deterioration. The study showed that patients who received AI-generated alerts were 43% more likely to have their care escalated and had a lower risk of death.
Researchers used an advanced AI tool to identify rare coding variants in 17 genes linked to coronary artery disease, shedding light on its molecular basis. The findings could lead to novel risk identification and treatment targets for cardiovascular care.
Researchers will study FSH's role in obesity, osteoporosis, and Alzheimer's disease. The grant aims to develop new treatments for these conditions and improve quality of life for older adults worldwide.
Researchers from Mount Sinai presented three studies on obstructive sleep apnea (OSA) at SLEEP 2024, exploring its effects on thalamic activity, overnight memory performance, and symptom improvement with CPAP treatment. The findings suggest that OSA can impair cognitive function and that hypoxic burden may predict clinical improvement.
Researchers identified a genetic cause of intellectual disability, caused by mutations in the non-coding gene RNU4-2, which affects tens of thousands of people worldwide. The discovery is significant, as it represents one of the most common single-gene genetic causes of neurodevelopmental disorders.
A clinical trial led by Mount Sinai researchers shows zodasiran, an RNA inhibitor targeting ANGPTL3, significantly reduces various types of cholesterol and triglycerides. The therapy also lowers apolipoprotein B, a lipid-transporting protein linked to heart disease.
A groundbreaking study published in Nature Neuroscience provides new insights into brain cell communication and opens the door to innovative treatment strategies for Alzheimer's disease. The research team identified a novel way to potentially slow down or halt disease progression by manipulating the plexin-B1 protein.
Two studies published in Science reveal significant advances in understanding the molecular biology of neuropsychiatric disease, including a comprehensive map of regulatory components of the brain. The research provides critical insights into the pathogenesis of mental health disorders and holds promise for therapeutic applications.
Researchers from Mount Sinai will present new research on long COVID, lung cancer, asthma, and sleep apnea at the ATS 2024 International Conference. The studies aim to improve diagnosis and care for these conditions.
A study published by the Icahn School of Medicine at Mount Sinai found that generative AI models like GPT-4 can accurately predict hospital admissions from limited records. The research suggests that AI could support doctors in emergency rooms with quick, informed decisions about patient admissions.
Researchers designed a regenerative medicine therapy to speed up diabetic wound repair using tiny fat particles loaded with genetic instructions. The treatment targeted problem-causing cells and reduced swelling, promoting faster and more effective wound closure.
Researchers at Mount Sinai identified genetic connections between inflammatory bowel disease (IBD) and Parkinson’s disease (PD), highlighting potential for joint therapeutic strategies. The study found mutations in the LRRK2 gene as a common element linking both conditions, with implications for innovative treatments.
Researchers have shed light on the mechanisms by which psychedelic drugs, such as LSD and psilocybin, bind to and activate serotonin receptors. The study highlights the potential therapeutic benefits of these compounds in treating depression and anxiety disorders.